<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04716790</url>
  </required_header>
  <id_info>
    <org_study_id>Ultrasound Debridement</org_study_id>
    <secondary_id>20/738-EC_P</secondary_id>
    <nct_id>NCT04716790</nct_id>
  </id_info>
  <brief_title>Comparison Between the Effect of Ultrasound Debridement and Conventional Treatment in Diabetic Foot Ulcers (DFU).</brief_title>
  <official_title>Randomized Clinical Trial to Elucidate the Effects of Low Frequency Ultrasound Debridement (LFU), in Patients With Diabetic Foot Ulcers, Compared to Its Conventional Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Complutense de Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yolanda García Álvarez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Francisco Javier Álvaro Afonso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Complutense de Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aimed to elucidate the effects of ultrasound debridement on the area and&#xD;
      healing of diabetic foot ulcers compared to their conventional treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">June 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 18, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized and controlled parallel clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>The clinician who performs the cures, photographs and data collection is different from the clinician who performs the application of ultrasound debridement. Therefore, the evaluator will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Healing Rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Total epithelialization of the wound.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Healing Time</measure>
    <time_frame>12 weeks</time_frame>
    <description>Time from the inclusion of the wound in the study until its total epithelialization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wound Size</measure>
    <time_frame>12 weeks</time_frame>
    <description>Planimetric measurements of wound size will be made using Visitrak (Smith &amp; Nephew, Hull, UK).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound Conditions</measure>
    <time_frame>12 weeks</time_frame>
    <description>The wound bed tissue will be evaluated for the presence, quality and consistency of the granulation tissue using a validated wound scoring system, with scores ranging from a minimum of zero points to a maximum of seven points (Wollina Score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcutaneous oxygen pressure (TcPO2)</measure>
    <time_frame>baseline and week 7</time_frame>
    <description>Two measurements will be made, one at the initial visit and the other at the final visit, and possible variations will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>12 weeks</time_frame>
    <description>It will be assessed using a numerical scale of pain that receives values between zero and ten, understanding zero as the absence of pain and ten as the maximum pain bearable by the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>baseline and 12 week</time_frame>
    <description>It will be assessed using the SF-36 health-related quality of life questionnaire at the beginning and end of the study. This questionnaire receives values between zero and one hundred so that the higher the score, the better the patient's health status.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Ultrasounds once a week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo the application of ultrasound therapy with a frequency of once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultrasounds once every two weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo the application of ultrasound therapy with a frequency of once every two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be treated using the conventional treatment established by the protocol of the Diabetic Foot Unit of the University Podiatry Clinic of Complutense University of Madrid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound Debridement</intervention_name>
    <description>Ultrasounds debridement is performed using an SONOCA 185 device (Söring GmbH, Germany). The ultrasounds device generates an ultrasound low frequency of 25kHz and is equipped with three instruments with different sonotrode shapes. The choice of sonotrode depends on wound depth. The ultrasounds instrument piezoelectrically transforms the electrical energy delivered from the ultrasound device into mechanical oscillations in the sonotrode tip.</description>
    <arm_group_label>Ultrasounds once a week</arm_group_label>
    <arm_group_label>Ultrasounds once every two weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional Treatment</intervention_name>
    <description>Conventional Treatment based on international guidelines for diabetic foot</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients ≥18 years old.&#xD;
&#xD;
          -  Type 1 or type 2 diabetes mellitus with HbA1c ≤ 10%.&#xD;
&#xD;
          -  DFU grades IA, IIA, IB, IIB, IC, IIC, ID, IID, according to the University of Texas&#xD;
             Classification.&#xD;
&#xD;
          -  DFU grades PEDIS 1-Absence of Infection, PEDIS 2-Mild infection and PEDIS 3-Moderate&#xD;
             infection, according to the PEDIS-IDSA Classification.&#xD;
&#xD;
          -  Wound size between 1 cm² and 30 cm².&#xD;
&#xD;
          -  Evolution time DFU between 1 and 24 months.&#xD;
&#xD;
          -  Ankle-brachial index (ABI) ≤0.9 and ankle systolic blood pressure (ASBP) ≥70mmHg, or&#xD;
             toe systolic blood pressure (TSBP) ≥50mmHg, ABI&gt;0.9, TSBP ≥50mmHg and toe-brachial&#xD;
             index (TBI) ≤0.7&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Critical limb ischemia patients with ABI≤0.5 and ASBP&lt;70mmHg or TSBP&lt;50mmHg.&#xD;
&#xD;
          -  Clinical suspicion of osteomyelitis.&#xD;
&#xD;
          -  Pregnant or lactating women or women of childbearing potential who are not using&#xD;
             effective contraception.&#xD;
&#xD;
          -  Patients diagnosed with hepatitis or human immunodeficiency virus (HIV)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yolanda García Álvarez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complutense University of Madrid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sebastián Flores Escobar</last_name>
    <phone>667857971</phone>
    <phone_ext>+34</phone_ext>
    <email>jhflores@ucm.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francisco Javier Alvaro Afonso</last_name>
    <phone>91 394 1535</phone>
    <phone_ext>+34</phone_ext>
    <email>alvaro@ucm.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complutense University</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastián Flores</last_name>
      <phone>667857971</phone>
      <phone_ext>+34</phone_ext>
      <email>jhflores@ucm.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Complutense de Madrid</investigator_affiliation>
    <investigator_full_name>Sebastian Flores Escobar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Diabetic Foot</keyword>
  <keyword>Diabetic Foot Ulcer</keyword>
  <keyword>Ultrasound Debridement</keyword>
  <keyword>Ultrasonic Debridement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

